TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Food-based Solutions for Optimal Vitamin D Nutrition and Health Through the Life Cycle (ODIN) Junior
Brief Summary: The main purpose of this study is to investigate whether and in which doses vitamin D intake is needed in order to maintain an adequate vitamin D status in 4-8 year-old Danish children during wintertime.


Options:
A: Arm Label: Vitamin D (10 microgram/day); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Arm Label: Vitamin D (20 microgram/day); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Arm Label: Placebo control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Vitamin D (10 microgram/day), Vitamin D (20 microgram/day)
B: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D2; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3
D: Arm Label: RUTF with Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D, Dietary Supplement: Ready to Use Therapeutic Food (RUTF) | Arm Label: RUTF with Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Ready to Use Therapeutic Food (RUTF) | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): RUTF with Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Ready to Use Therapeutic Food (RUTF); Assigned to Arm(s): RUTF with Placebo, RUTF with Vitamin D

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Cognitive Functional Therapy on Patients With Non-specific Chronic Low Back Pain: a Multi-centre Randomized Trial
Brief Summary: The purpose of this study is to evaluate whether individual cognitive functional therapy (CFT), when compared to group exercise classes is effective in reducing pain and disability in patients with non-specific chronic low back pain.


Options:
A: Intervention Type: PROCEDURE; Name: Mod. functional restoration-Individ. dynamic back-muscle; Assigned to Arm(s): N/A
B: Arm Label: Exercise and advise to stay active; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Arm Label: Rest and use of flexible lumbar belt; Type: EXPERIMENTAL; Interventions: Other: Restitution | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise and advise to stay active | Intervention Type: OTHER; Name: Restitution; Assigned to Arm(s): Rest and use of flexible lumbar belt
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General health talk, Behavioral: Handout of The Back Book, Behavioral: Back exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Handout of The Back Book, Behavioral: Back exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Back exercise | Intervention Type: BEHAVIORAL; Name: General health talk; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Handout of The Back Book; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Back exercise; Assigned to Arm(s): 1, 2, 3
D: Arm Label: Individual Cognitive Functional Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Cognitive Functional Therapy | Arm Label: Group Exercise Classes; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group Exercise Classes | Intervention Type: BEHAVIORAL; Name: Individual Cognitive Functional Therapy; Assigned to Arm(s): Individual Cognitive Functional Therapy | Intervention Type: BEHAVIORAL; Name: Group Exercise Classes; Assigned to Arm(s): Group Exercise Classes

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Validation of a Simple Questionnaire to Assess Gastrointestinal Symptoms After Oral Ferrous Sulphate Supplementation.
Brief Summary: Oral iron supplementation is often associated with rapid onset of gastrointestinal side-effects. The aim of this study was to develop and trial a short, simple questionnaire to capture these early side-effects and to determine which symptoms are more discriminating.

The study was a double-blind placebo-controlled randomized parallel trial with one week treatment followed by one week wash-out. Subjects were randomized into two treatment groups (n=10/group) to receive either ferrous sulphate (200 mg capsules containing 65 mg of iron) or placebo, both to be taken at mealtimes twice daily during the treatment period. Subjects completed the questionnaires daily for 14 days. The questionnaire included gastrointestinal symptoms commonly reported to be associated with the oral intake of ferrous iron salts (i.e. nausea, vomiting, heartburn, abdominal pain, diarrhoea, and constipation).


Options:
A: Arm Label: Folic Acid and Iron; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Folic Acid and Iron | Arm Label: Folic Acid; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic Acid | Arm Label: Multivitamins, Folic Acid, and Iron; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins, Folic Acid, and Iron | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins, Folic Acid, and Iron; Assigned to Arm(s): Multivitamins, Folic Acid, and Iron | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid and Iron; Assigned to Arm(s): Folic Acid and Iron | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid; Assigned to Arm(s): Folic Acid
B: Arm Label: Ferrous sulfate; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: ferrous sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: ferrous sulfate; Assigned to Arm(s): Ferrous sulfate | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Iron supplements; Type: EXPERIMENTAL; Interventions: Dietary Supplement: ferrous gluconate | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: ferrous gluconate; Assigned to Arm(s): Iron supplements
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: GB (Florestor) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: GRALB | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: GC (placebo) | Intervention Type: DRUG; Name: GB (Florestor); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: GRALB; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: GC (placebo); Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating the Real-world Effectiveness of Varenicline and Bupropion for Long-term Smoking Cessation
Brief Summary: Clinically proven medications such as nicotine replacement therapy, bupropion and varenicline are available to help smokers quit but there are not widely used. The primary objective of this study is to evaluate the real-world long-term effectiveness of of bupropion and varenicline treatment in a community sample of smokers interested in quitting. The investigators hypothesize that varenicline treatment will result in higher quit rates at end of treatment and at one year after treatment compared to bupropion. Smoking status will be biochemically confirmed at various time points using salivary cotinine measures. Furthermore, since 50% of the variation in quit success is genetically determined, and the effectiveness of different cessation medication may differ considerably in sub-groups of smokers carrying certain genetic variants, the investigators will collect saliva samples from consenting participants to evaluate the moderating effect of genetics on treatment response.


Options:
A: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bupropion + Naltrexone | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bupropion + Naltrexone; Assigned to Arm(s): 2
C: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Weekly Motivational Emails | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Weekly Motivational Emails | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: BEHAVIORAL; Name: Weekly Motivational Emails; Assigned to Arm(s): Bupropion, Varenicline
D: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Tailored/No Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended Tailored Counseling + NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Intervention Type: DRUG; Name: Nicotine polacrilex, Bupropion; Assigned to Arm(s): Brief Treatment, Extended NRT, Extended Tailored Counseling + NRT, Tailored/No Extended NRT

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Randomized, Placebo-Controlled, Crossover Study of the Effect of the Nicotine Nasal Spray and Varenicline on Cigarette Smoking Following Methadone Dosing in Methadone-Maintained Patients
Brief Summary: The objective is to provide a preliminary test of the ability of two pharmacological treatments, the nicotine nasal spray and varenicline, relative to placebos, to reduce smoking during the 4 hours following methadone dosing.


Options:
A: Arm Label: Order 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 2; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 3; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 4; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Intervention Type: DRUG; Name: Nicotine Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2
C: Arm Label: Drug Selegiline; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: matching placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): Drug Selegiline | Intervention Type: OTHER; Name: matching placebo; Assigned to Arm(s): Matching placebo
D: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Randomized, Placebo-Controlled, Crossover Study of the Effect of the Nicotine Nasal Spray and Varenicline on Cigarette Smoking Following Methadone Dosing in Methadone-Maintained Patients
Brief Summary: The objective is to provide a preliminary test of the ability of two pharmacological treatments, the nicotine nasal spray and varenicline, relative to placebos, to reduce smoking during the 4 hours following methadone dosing.


Options:
A: Arm Label: Nicotine E-Cigarette and Counseling; Type: EXPERIMENTAL; Interventions: Other: Nicotine E-Cigarette, Behavioral: Counseling | Arm Label: Non-Nicotine E-Cigarette and Counseling; Type: OTHER; Interventions: Other: Non-Nicotine E-Cigarette, Behavioral: Counseling | Arm Label: Counseling; Type: OTHER; Interventions: Behavioral: Counseling | Intervention Type: OTHER; Name: Nicotine E-Cigarette; Assigned to Arm(s): Nicotine E-Cigarette and Counseling | Intervention Type: OTHER; Name: Non-Nicotine E-Cigarette; Assigned to Arm(s): Non-Nicotine E-Cigarette and Counseling | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Counseling, Nicotine E-Cigarette and Counseling, Non-Nicotine E-Cigarette and Counseling
B: Arm Label: E-Cig Zero Nicotine; Type: SHAM_COMPARATOR; Interventions: Device: E-Cig Zero Nicotine | Arm Label: E-Cig 24mg Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Device: E-Cig 24mg Nicotine | Intervention Type: DEVICE; Name: E-Cig Zero Nicotine; Assigned to Arm(s): E-Cig Zero Nicotine | Intervention Type: DEVICE; Name: E-Cig 24mg Nicotine; Assigned to Arm(s): E-Cig 24mg Nicotine
C: Arm Label: Order 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 2; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 3; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 4; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Intervention Type: DRUG; Name: Nicotine Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4
D: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Randomized, Placebo-Controlled, Crossover Study of the Effect of the Nicotine Nasal Spray and Varenicline on Cigarette Smoking Following Methadone Dosing in Methadone-Maintained Patients
Brief Summary: The objective is to provide a preliminary test of the ability of two pharmacological treatments, the nicotine nasal spray and varenicline, relative to placebos, to reduce smoking during the 4 hours following methadone dosing.


Options:
A: Arm Label: Order 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 2; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 3; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 4; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Intervention Type: DRUG; Name: Nicotine Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4
B: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Tailored/No Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended Tailored Counseling + NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Intervention Type: DRUG; Name: Nicotine polacrilex, Bupropion; Assigned to Arm(s): Brief Treatment, Extended NRT, Extended Tailored Counseling + NRT, Tailored/No Extended NRT
C: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
D: Arm Label: Varenicline & nicotine patches; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patches | Arm Label: Varenicline & placebo patches; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo (nicotine patches) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline & nicotine patches, Varenicline & placebo patches | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Varenicline & nicotine patches | Intervention Type: DRUG; Name: Placebo (nicotine patches); Assigned to Arm(s): Varenicline & placebo patches

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Therapeutic Effect of Bandage Contact Lenses on Dry Eye Caused by Sjogren's Syndrome
Brief Summary: The purpose of this study is to evaluate the therapeutic effect and safety of therapeutic bandage contact lenses treating dry eye caused by Sjögren's syndrome.


Options:
A: Arm Label: Autologous serum -Systane; Type: OTHER; Interventions: Drug: Autologous serum - Systane | Arm Label: Systane- Autologous serum; Type: OTHER; Interventions: Drug: Systane - Autologous serum | Intervention Type: DRUG; Name: Autologous serum - Systane; Assigned to Arm(s): Autologous serum -Systane | Intervention Type: DRUG; Name: Systane - Autologous serum; Assigned to Arm(s): Systane- Autologous serum
B: Arm Label: UCB eyedrops, single arm; Type: N/A; Interventions: Other: UCS eyedrops | Intervention Type: OTHER; Name: UCS eyedrops; Assigned to Arm(s): UCB eyedrops, single arm
C: Arm Label: Severe dry eye; Type: EXPERIMENTAL; Interventions: Drug: 0.02% Fm, SH, Drug: 0.02% Fm, SH, 0.05% CsA, Other: 0.02% Fm, SH, tBCL, Drug: 0.02% Fm, SH, AS | Intervention Type: DRUG; Name: 0.02% Fm, SH; Assigned to Arm(s): Severe dry eye | Intervention Type: DRUG; Name: 0.02% Fm, SH, 0.05% CsA; Assigned to Arm(s): Severe dry eye | Intervention Type: OTHER; Name: 0.02% Fm, SH, tBCL; Assigned to Arm(s): Severe dry eye | Intervention Type: DRUG; Name: 0.02% Fm, SH, AS; Assigned to Arm(s): Severe dry eye
D: Arm Label: Normal; Type: N/A; Interventions: N/A | Arm Label: Dry Eye Disease; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Helping Hand (AHH) to Activate Patient-Centered Depression Care Among Low-Income Patients
Brief Summary: Study Hypotheses (Ho) and Research Questions (RQ):

* Ho1. AHH will significantly improve patient depression treatment acceptance/adherence and depression symptoms vs UC at 6 and 12 months post-baseline.
* Ho2. A Helping Hand (AHH) will significantly improve and sustain patient self-care management in Self-Efficacy for Managing Chronic Disease (SEMCD) and Quality of Life vs UC at 6 and 12 months post-baseline.
* RQ1. What is the association between depression symptoms and concurrent chronic illness self-care management over time by group?
* RQ2. Will AHH reduce hospitalizations and Emergency Room visits and improve clinic appointment-keeping?
* RQ3. Will patient care satisfaction and reported barriers to self-care management vary by study group?
* RQ4. What factors are identified via qualitative assessments of patients, promotoras, Department of Health Services (DHS) medical and social work providers, and DHS clinic/organizational leadership regarding satisfaction with, sustainable uptake of, and suggested modifications of the AHH promotora delivery model?
* RQ5. What potential technology applications would enhance promotoras delivering patient-centered self-care training and resource navigation, communicating and integrating care with DHS, and disseminating AHH?


Options:
A: Arm Label: ESL Health Literacy Classes; Type: OTHER; Interventions: Behavioral: ESL Health Literacy Classes | Intervention Type: BEHAVIORAL; Name: ESL Health Literacy Classes; Assigned to Arm(s): ESL Health Literacy Classes
B: Arm Label: Case-Management for Behavior Change; Type: EXPERIMENTAL; Interventions: Behavioral: Vivamos Activos Fair Oaks Program | Arm Label: Case-Management plus Home Visits; Type: EXPERIMENTAL; Interventions: Behavioral: Vivamos Activos Fair Oaks Program | Arm Label: Usual Primary Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Vivamos Activos Fair Oaks Program | Intervention Type: BEHAVIORAL; Name: Vivamos Activos Fair Oaks Program; Assigned to Arm(s): Case-Management for Behavior Change, Case-Management plus Home Visits, Usual Primary Care
C: Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Print brochure | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: mMammogram | Intervention Type: BEHAVIORAL; Name: mMammogram; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Print brochure; Assigned to Arm(s): Control group
D: Arm Label: A Helping Hand (AHH); Type: EXPERIMENTAL; Interventions: Behavioral: Self-care management | Arm Label: Usual Care (UC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-care management; Assigned to Arm(s): A Helping Hand (AHH)

Answer: D